This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Matsunaga T, Yamamoto M, Mimura H, Ohta T, Kiyoki M, Ohba T, Naruchi T, Hosoi J, Kurkoi T (1990) J Derm 17:135–142
Matsumoto K, Hashimoto K, Kiyoki M, Yamamoto M, Yoshikawa K (1990) J Derm 17:97–103
Kawashima H, Hoshina K, Hashimoto Y, Takeshita T, Ishimoto S, Noguchi T, Ikekawa N, Norisaki M, Orimo H (1977) FEBS Letters 76:177–181
Kato T, Rokugo M, Teruui T, Tagami H (1986) Br J Derm 115:431–433
Gerritsen MJP, Boezeman JBM, Van Vlijmen-Willems IMJJ, Van de Kerkhof PCM (1994) Br J Derm 131:57–63
Bettinger J, Gloor M, Fluhr J, Gehring W (1996) Zeitschrift für Haut-und Geschlechtskrankheiten 71:28–32
Baadsgaard O, Traulsen J, Roed-Petersen J, Jakobsen HB (1995) J Derm Treatment 6:115–150
Mortensen JT, Lichtenberg J, Binderup L (1996) J Invest Derm Symposia Proceedings 1:60–63
Ohta T, Yamamoto M, Takada Y, Mimura H, Matsunaga T, Kiyoki M, Ohba T, Naruchi T (1990) Xenobiotic Metabolism and Disposition 5:39–53
Fachinformation Curatoderm (1995) Bundesverband der Pharmazeutischen Industrie
Yamamoto M, Ohta T, Mimura H, Kiyoki M, Ohba T, Naruchi T (1990) Xenobiotic Metabolism and Disposition 5:53–64
Muller-Lehar J, US 5247091 A, zit. nach CA (1994) 120:106526
Mochida J, Sakaniski K, Okazaki H, Soeda M, JP 03145471, zit. nach CA (1991) 115:207872
Jane J, McKinnon A; Flanagan RJ (1985) J Chromatogr 323(2):191–225
Musumarra G, Scarlata G, Romano G, Clementi S et al. (1984) J Chromatogr Sci 22(12):538–547
Wagstaff AJ, McTavish D (1994) Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease. Drugs and Aging 4:510–540
Lamy PP (1994) The role of cholinesterase inhibitor in Alzheimer’s diesease. CNS Drugs 1:146–165
Kurz A, Marquard R, Mosch D (1995) Tacrine: progress in treatment of Alzheimers disease? Zeitschrift für Gerontologie und Geriatrie 28:163–168
Foster NL, Petersen RC, Gracon SI, Lewis K and the Tacrine Study Group (1996) An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer’s disease. Dementia 7:260–266
Fredj G, Deitlin F, Jasmin C, Maurisson G, Barbier M (1992) Open trial of tacrine therapy in 70 HIV-infected patients. Int J Clin Pharmacol Ther Toxicol 30:313–316
Bajgar J, Fusek J, Skopec F (1994) Changes in cholinesterases in the blood and some tissues following administration of tacrin and its two derivatives to rats. Neurochemistry International 24:555–558
Trzepacz PT, Ho V, Mallavaqrapu H (1996) Cholinergic delirium and neurotoxicity associated with tacrine for Alzheimer’s dementia. Psychosomatics 37:299–301
Lebert F, Hasenbroekx C, Pasquier F, Petit H (1996) Convulsive effects of tacrine. Lancet 347:1339–1340
Forgue ST, Reece PA, Sedman AJ, de Vries TM (1996) Inhibition of tacrine oral clearance by cimetidine. Clin Pharmacol Ther 59:444–449
Wood DM, Ford JM, Roberts CJC (1996) Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride) a: potential agent for Alzheimer’s disease. Eur J Clin Pharmacol 50:115–119
Mar 27, S. 1339
Boehringer Ingelheim (1997) Alna-Monographie, 2. Aufl.
Mannhold R (1986) Drug Fut 11:293–295
Imai K, Niigata K, Fujikura T, Hashimoto S, GB 2006772 und Niigata K, Fujikura T, Hashimoto S, Takenaka T, EP 34432 beide an Yamanouchi Pharma Co., Ltd., zit. nach Lit.2
Soeishi Y, Kobori M, Kobayashi SI, Higuchi S (1990) J Chromatogr 533:291–296
Wilde MI, McTavish D (1996) Tamsulosin. a review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 52:883–898
Chapple CR, Burt RP, Andersson PO (1994) Alpha 1-adrenoceptor subtypes in the human prostate. Br J Urol 74:585–589
Hatano A, Takahashi H, Tamaki (1994) Pharmacological evidence of distinct α1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113:723–728
Lee E, Lee C (1997) Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80:606–611
Chueh S-C, Guh J-H, Chen J (1996) Tamsulosin inhibits potently the tension responses of human prostate to field stimulation: an important understanding of its signal transduction pathway. Proc Am Urol Assoc 155(Suppl):576A
Breslin D, Fields DW, Chou T-C (1993) Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha 1-adrenergic antagonists in the prostate. J Urol 149:395–399
Soeishi Y, Matsushima H, Watanabe T, Higuchi S, Cornelissen K, Ward J (1996) Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica 26:637–645
Flohé L, Böhlke H, Frankus E, Kim SMA, Lintz W, Loschen G, Michel G, Mäller B, Schneider J, Seipp U, Vollenberg W, Wilsmann K (1983) Arzneim-Forsch (Drug-Res.) 33(II):1240–1248
Johnson G, Furlan LE, Aoki N, Lefer AM (1990) Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. Circ Res 66:1362–1370
Schneider J (1991) Beneficial effects of the prostacyclin analogue taprostene on cardiovascular, pulmonary and renal disturbances in endotoxin-shocked rabbits. Eicosanoids 4:99–105
Virgolini I, Fitscha P, Sinzinger H, Barth H (1990) Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers. Eur J Clin Pharmacol 38:347–350
Michel O, Matthias R (1991) Plazebokontrollierte Doppelblindstudie zur Hörsturzbehandlung mit einem stabilen Prostacyclinanalog. Laryngorhinootologie 70:255–259
Virgonlini I, Fitscha P, O’Grady J, Barth H, et al. (1989) Effects of taprostene, a chemically stable prostacyclin analogue, in patients with ischaemic peripheral vascular disease: a placebo controlled double-blind trial. Prostaglandins Leukot Essent Fatty Acids 38:31–35
Heinz M, Theiss W, van de Flierdt E, Sohngen M (1996) Der Einfluß von Taprosten auf Thrombozytenaktivierung und klinischen Verlauf nach perkutaner transluminaler Angioplastie. Vasa 25:65–72
Bar FW, Meyer J, Michels R, Uebis R, et al. (1993) The effect of taprostenen in patients with acute myocardial infarction treated with thrombolytic therapy: results of the START study. Saruplase Taprostenen Acute Reocclusion Trial. Eur Heart J 14:1118–1126
Carlsson JIL, Petersen HGJ, Stamvik AR (Aktiebolag Leo) EP 106123 zit nach Lit. 2
(1986) Drugs Fut 11:585-587
Roed H, Vindelov LL, Spang-Thomsen M, Christensen IJ, Hansen HH (1987) Cancer Chemother Pharmacol 19:315–318
Hartley-Asp B, Christensson PI, Gunnarsson K, Gunnarsson PO, Jensen G, Polacek J, Stamivik A (1988) Investigational New Drugs 6:19–30
Smyth JF, Macpherson JS, Warrington PS, Kerr ME, Whelan JM, Combleet MA, Leonard RCF (1987) Eur J Cancer Clin Oncol 23:1845–1849
Vibe-Petersen J, Bork E, Moller H, Hansen HH (1987) Eur J Cancer Clin Oncol 23:1837–1843
Gundersen S, Dombernowsky P, Cavalli F, Bruntsch U, Renard J, Van Glabbeke M, Pinedo H (1989) Eur J Cancer Clin Oncol 25:1095–1097
Carell S.A., Robinson C.P. (1989) Drugs Fut 14:1169–1174
Mar 31, S. 1467
Jurisson S (1990) Drugs Fut 15:1085–1086
Mar 31, S. 1467
Mar 31, S. 1467
Robinson C, Castañer J (1995) Drugs Fut 20:251–255
Mar 31, S. 1467
Rose R, Prescott MC, Herman KJ (1990) J Nucl Med 31(6):978–984
Sadek S, Owunwanne A, Abdel-Dayem HM, Yacoub T (1989) Lymphology 22(4):157–166
Mar 31, S. 1467
Nielsen Sl, Pedersen B, Svalastoga E, Vittas D, Reiman I (1990) Eur J Nucl Med 16:639–641
Mar 31, S. 1467
Rijke AM, Croft BY, de Jongste AB, Camps JA (1990) J Nucl Med 31(6):990–998
Atkins HL (1990) Int J Rad Appl Instrum B:17(1):3–11
Schmidtchen M, Reichelt HG (1990) Röntgenblätter 43(6):251–255
Mar 31, S. 1467
B Anz (1990) 143:3950
Imaeda T, Inoue A, Doi H, Ozawa N (1990) Clin Nucl Med 15(7):504–506
Hoffken H, Ebel H, Bongers H, Lange H, Joseph K (1987) Transplant Proc 19(1 Pt 2):1675–1676
Itoh H, Kanamori M, Takahashi N (1990) Clin Nucl Med 15(2):124–125
Mar 31, S. 1467
Mar 31, S. 952
Catena E, Maselli R, Pacia A (1993) Riv Ital Biol Med 13:201–213
Gianotti A (1994) Clin Ter 145:283–285
Glaxo S. p. A., DE 3628215 A1 26.02.1987; zit. nach CA 107:23240
Tolomeo M, Gancitano RA, Musso M, Poretto F, et al. (1994) Effects of R-enantiomer and L-enantiomer of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype. Haematologica 79:328–333
Kadin SB (1985) EP 156603, zit. nach CA (1986) 104:109468a
Moore PF, Larson DL, Otterness IG et al. (1996) Tenidap, a structurally novel drug for the treatment of arthritis: Antiinflammatory and analgesic properties. Inflamm Res 45:54–61
Proudman KE, McMillan RM (1991) Are tolfenamic acid and tenidap dual inhibitors of 5-Lipoxygenase and cyclooxygenase? Agents Actions 34:211–216
Vane JR (1971) Inhibition of prostaglandin synthesis as mechanism of aspirin-like drugs. Nat New Biol 231:232–235
Lieb K, Fiebisch BL, Hüll M, Berger M, Bauer J (1997) Potent inhibition of interleukin-6 expression in a human astrocytoma cell line by tenidap. Cell Tissue Res, 288(2):251–257
Breedveld F (1994) Tenidap: a novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis. Scand J Rheumatol Suppl 100:31–44
Blackburn WD Jr, Loose LD, Heck LW, Chatham WW (1991) Tenidap, in contrast to serveral available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase. Arthritis Rheum 34(2):211–216
Madhok R (1995) Tenidap. Lancet 346:481–485
Gardner J, Wilner KD, Hansen RA, et al. (1995) Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects. Br J Clin Pharmacol 39(suppl):11–15
Coates E, Mesure R (1995) Pharmacokinetics of tenidap sodium administered with food or antacids in healthy volunteers. Br J Clin Pharmacol 39:17–19
Davis JS, Loose LD, Borger AP (1988) Clinical efficacy of CP-66,248 (5-cyclo-2,3-dihydro-2-oxo-3-(2-thienyl-carbonyl)-indonlyl-1-carboxamide) in osteoarthritis (abstract). Arthritis Rheum 31 (Suppl 4):72
Smith DM, Johnson JA, Loeser R, et al. (1990) Evaluation of tenidap (CP-66, 248) on human neutrophil arachidonic acid and metabolism, chemotactic potential and clinical efficacy in the treatment of rheumatoid arthritis. Agent Actions 31:102–109
Wylie G, Appelboom T, Bolten W, et al. (1995) A 24-week comparative study of tenidap, a cytokine-modulating anti-rheumatic drug and diclofenac in rheumatoid arthritis. Br J Rheumatol 34:554–563
Martinez BM, Domingo P (1997) Acute eosinophilic pneumonia associated with tenidap. Br Med J 314:349
Apselsoff G, Wilner KB, von Deutsch DA, et al. (1995) Tenidap sodium decreases renal clearance and increases steady-state concentrations of lithium in healthy volunteers. Br J Clin Pharmacol 39:25–28
Ragheb M, Ban TA, Buchanan D, Frölich JC (1980) Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level. J Clin Psychiatry, 41(11):397–398
Daly JS, Boyle J, Roberts C, et al. (1986) Interaction between methotrexate and non steroidal antiinflammatory drugs. Lancet 1:559
Drugs Fut (1993) 18:875-876
Drugs Fut (1990) 15:898-901
Drugs Fut (1990) 15(9):902
Walsman SA, Vitow C, Osborne B, Gillen L, et al. (1996) Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers J Clin Pharmacol 36(5):462–468
Vane JR, Botting RM (1995) A better understanding of anti-inflammatory drugs based on isoforms of COX. Adv Prost Thromb Leuko Res 23:41–48
Depre M, Van Hecken A, Verbesselt R, Verpooten GA, et al. (1996) Biochemical acitivity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. Int J Clin Pharmacol Res 16(1):1–8
Vane JR, Botting R (1996) Overview — mechanisms of action of anti-inflammatory drugs. IN: Vane JR, Botting J, Botting R (eds.) improved anti-inflammatory drugs. COX-2 enzyme inhibitors. Lancester: Kluwer Academic Publisher
Tam SS, Lee DH, Wang EY, Munroe DG, et al. (1995) Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities. J Biol Chem 270(23):13948–13955
Higgs GA, Monacada S (1985) Leukotrienes in disease: implication for drug development. Drugs 30:1–5
Rainsford KD, Ying C, Smith F (1993) Selective effects of some 5-lipoxygenase inhibitors on synovial interleukin-1 (IL-1) production compared with IL-1 synthesis inhibitors. Agents Actions 39 Spec No:C186-C188
Argentieri DC, Ritchie DM, Ferro MP, Kirchner T, et al. (1995) Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 271(3):1399–1408
Kirchner T, Aparicio B, Argentierei DC, Lau CY, et al. (1997) Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Protaglandins Leukot Essent Fatty Acids 56(6):417–423
Willburger RE, Wittenberg RH, Kleemeyer KS, Hoos R, et al. (1996) Inhibition of eicosanoid release from synovial organ culture by incubation with tepoxalin and its acid metabolite. Prostaglandins 52(4):327–338
Lee DH, Tarn SS, Wang E, Tylor GR, e al. (1996) The NF-kappa B inhibitor, tepoxalin, supresses surface expression of the cell adhesion molecules CD62E, CD lib/CD 18 and CD106. Immunol Lett 1996 Nov; 53(2–3):109–113
Zhou L, Titchie D, Wang EY, Barbone AG, et al. (1994) Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A. J Immunol 153(11):5026–5037
Kazmi SM, Plante RK, Visconti V, Taylor GR, et al. (1995) Suppression of NF Kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J Cell Biochem 57(2):299–310
Ritchie DM, Argentieri DC, Aparicio BL, Plante RK, et al. (1995) Cytokine modulating activity of tepoxalin, a new potential antirheumatic drug. Int J Immunopharmacol 17(10):805–812
Rainsford KD, Ying C, Smith F (1996) Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. J Pharma Pharmacol 48(1):46–52
Robinson CP (1990) Tepoxalin. Drugs Future 30:1–5
Argentieri C, Anderson DW, Ritchie DM, Rosenthale ME, et al (1990) Tepoxalin (RWJ 20485) inhibits prostaglandin and leukotriene production in adjuvant arthritic rats and in dog knee joints challenged with sodium urate and immune complexes (abstract.) FASEB J 4:A1122
Baffa RB, Connelly CD, Martinez RP, Schupsky JJ, et al. (1995) Antinociceptive effects of a novel dual cyclooxygenase/5-lipoxygenase inhibitor (tepoxalin) and its primary (carboxylic acid) metabolite (RW 20142) in acutes tests in mice and rats. Drug Develop Res 36(2):81–90
Knight EV, Kimball JP, Keenan CM, Smith I, et al. (1996) Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam Appl Toxicol 33(1):38–48
Wallace JL, Cirino G, Cicala C, Anderson DW, et al. (1991) Comparison of the ulcerogenic properties of tepoxalin with those of non-steroidal anti-inflammatory drugs (NSAIDs): Agents Actions 34(1-2):247–250
Wallace JL, McCafferty DM, Carter L, McKNight W, et al. (1993) Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy? Gastroenterology 105(6):1630–1636
Johnson AG, Seideman P, Day RO (1993) Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance. Drug Saf 8(2):99–127
Nardi D, Leonardi A, Pennini R, Tajana A et al. (1993) Arzneim Forsch 43:28–34
Testa R, Guarneri L, Bernasconi P, Angelico P, et al. (1993) Effects of terflavoxate on stimulated contractions of urinary bladder in vitro. Arzneimittelforsch 43:122–128
Leonardi A, Cappelletti R, Nardi D, Giordano F (1993) Arzneim Forsch 43:356–362
Riederer P, Danielczyk W, Suchy I, Brücke T (1986) Drugs Fut 11:288–290
Cerny A, Benes J, Vachek J, Pesak M, Stuchlik J, Stuchlik M, Sedmera P, Flieger M, Vokoun J (1987) Coll Czech Chem Commun 52:1331–1339
Zikan V, Semonsky M, Rezabek K, Auskova M, Seda M (1972) Coll Czech Chem Commun 37:2600–2605
Steinegger E, Hänsel R (1972) Lehrbuch der Pharmakognosie, 3. Aufl., Springer Verlag, Berlin Heidelberg, S. 386–388
Tietze LF, Eicher T (1991) Reaktionen und Synthesen, 2. Aufl., Georg Thieme Verlag, Stuttgart, S.494–495
Mar 30, S. 1419
Mar 31, S. 1758
Hempel C (1876) Liebigs Ann Chem 180:71
Sword J (1925) J Chem Soc 127:1632
Mar 28, S. 693
Roberts SA, Jollow DJ (1980) Pharmacologist 22:423–430
Mar 30, S. 1419
Friedrich W (1988) Vitamins, Walter de Gruyter Verlag, Berlin, New York, S. 626
Friedrich W (1988) Vitamins, Walter de Gruyter Verlag, Berlin, New York, S. 653–656
Ebel S, Dorner W (1988) Jahrbuch Chemielabor, VCH Verlagsgesellschaft mbH, Weinheim, S. 135
Vergin H, Bishop GB (1980) Arzneim Forsch 30:317–319
Schlöbe R, Thijssen HHW (1982) J Chromatogr 230:212–215
Eur Pat Appl,EP71741A1 830216;zit. nach CA99:70752
Naber K, Vergin H, Weigand (1981) Infection 9:239–243
Mar 31, S. 217.3
Vergin H, Strobel K (1982) Eur J Drug Metab Pharmacokin 7:197–202
Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag:Bd. 3
Voisin H (1969) Materia medica des hom. Praktikers, Haug Verlag Heidelberg: S. 1172
Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag;. Bd. 3
Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag:Bd. 3
Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag: Bd. 3
Pretschner PD (1985) Myokardiale Szintigraphie mit 201Tl. In: H. Hundeshagen (Hrsg.) Diagnostik II Springer, Berlin, Heidelberg, New York (Nuklearmedizin, Bd. 15/ 3): 113–225
Bull U, Doliwa R, Kirsch CM, Roedla D, Strauer BE (1984) Die 201T1-SPECT in der funktionellen Beurteilung koronarstenotischer Veränderungen. Ergebnisse des Vergleichs von belastungsszintigraphischen mit koronarangiographischen Befunden. Z. Kardiol. 73:313–320
Hör G, Bussmann WD (Hrsg.) (1984) Kardiovaskuläre Nuklearmedizin: Ambulanz und Intensivstation. Fischer, Stuttgart, New York
Mar 31, S. 1468
Mar 29, S. 688
Roth C (1988) Krebserzeugende Stoffe, 2. Aufl., Carl Roth GmbH & Co., Karlsruhe, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart
Beil Grundwerk, Bd. 24, S.476
Klason P, Carlson T (1906) Ber Dtsch Chem Ges 39:732–738
Merck-Katalog Reagenzien, Diagnostica, Chemikalien (1992/1993)
Li NC, Manning RA (1955) J Am Chem Soc 77:5225–5228
Römpps Chemie-Lexikon (1983) 8. Aufl., Frankh’sche Verlagshandlung, Stuttgart
Gottron HA, Schönfeld W (1958) Dermatologie und Venerologie, Thieme-Verlag, Stuttgart, Bd. II, Teil 1, S. 388
US Pat. 2′552′584; 2′560′596
US Pat. 2′173′067
Drugs Fut (1983) 8(7):627
Galaktionov V, Shmeelev V, Bunina Z, Nosova L, Novikova N, Kudryavtseva T, Korobko V, Vyacheslav G, Boldyreva E (1996) Izobreteniya 11:182–183
Miruton J; Jpn Kokai Tokkyo Koho, Patent JP 07002693 A2 950106 Heisei
Wang S, Eur Pat Appl, S.23; Patent EP 341935 A2 891115
Goldstein AL (Hrsg.) (1983) Thymic Hormon Lymphokines, Plenum, New York, N.Y., Meeting Date 1983:165-173; zit. nach CA (1985) 202418
Patent FR2493310A1820507
Low T, McClure J, Nayler P, Spangelo B, Goldstein A (1983) J Chromatogr 260:533–544
Umagat H, Kucera P, Wen L (1982) J Chromatogr 239:463–474
Badamchian M, Strickler M, Stone M, Goldstein A (1989) J Liq Chromatogr 12(5):845–860
Andersen KE, Braestrup C, Grønwald FC, Jørgensen AS, Nielsen EB, Sonnewald U, Sørensen PO, Suzdak PD, Knutsen US (1993) J Med Chem 36:1716–1725
Chorghade MS, Petersen H, Lee EC, Bains S (1996) Pure Appl Chem 68:761–763
Rustum AM, Gutierrez L (1990) J Chromatogr 503(1):115–125
Gustavson LE, Chu S (1992) J Chromatgr 574:313
Ben Menachem E (1995) International experience with tiagabin add-on therapy. Epilepsia 36 Suppl 6:14–21
Bialer M (1993) Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 24:441–452
Borden LA, Murali Dhar TG, Smith KE, Weinshank RL, Branchek TA, Gluchowski C (1994) Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 14;269: 219–224
Braestrup C, Nielsen EB, Sonnewald U, Knutsen LJ, Andersen KE, Jansen JA, Frederiksen K, Andersen PH, Mortensen A, Suzdak PD (1990) (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J Neurochem 54:639–647
Brodie MJ (1995) Tiagabine pharmacology in profile. Epilepsia 36 Suppl 6:7–9
Faingold CL, Randall ME, Anderson CA (1994) Blockade of GABA uptake with tiagabine inhibits audogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat. Exp Neurol 126:225–232
Fink Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG (1992) The gamma-aminobutryric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 220:197–201
Gao XM, Kakigi T, Friedman MB, Tamminga CA (1994) Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. J Neural Transm Gen Sect 95:63–69
Gustavson LE, Megnel HB (1995) Pharmacokinetics of tiagabine, a gamma-aminobutyric acid uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 36:605–611
Leach JP, Stolarek I, Brodie MJ (1995) Deliberate overdose with the novel anticonvulsant tiagabine. Seizure 4:155–157
Mengel H (1994) Tiagabine. Epilepsia 35 Suppl 5:81–84
Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJ, Sonnewald U, Braiestrup C (1991) Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196:257–266
Patsalos PN, Sander JWAS (1994) Newer antiepileptic drugs. Towards an improved risk-benefit-ratio. Drug Safety 11:37–67
Rekling JC, Jahnsen H, Mosfeldt Laursen A (1990) The effect of two lipophilic gamma-aminobutyric acid uptake blockers in CA1 of the rat hippocampal slice. Br J Pharmacol 99:103–106
Richens A, Chadwick DW, Duncan JS, Dam M, Gram L, Mikkelsen M, Morrow J, Mengel H, Shu V, McKelvy JF (1995) Adjunctive treatment of partial seizures with tiagabine: a placebo controlled trial. Epilepsy Res 21:37–42
Suzdak PD (1994) Lack of tolerance to the anticonvulsant effects of tiagabine following chronic (21 day) treatment. Epilepsy Res 19:205–213
Suzdak PD, Jensen JA (1995) A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36:612–626
Sveinbjornsdottir S, Sander JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS (1994) Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 3:29–35
Wilder BJ (1994) How about the new antiepileptic drugs? Can J Neurol Sci 21:17–20
Yamaguchi S, Rogawski MA (1992) Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res 11:9–16
DeVisser J, Coert A, Feenstra H, Van der Vies J (1984) Arzneim Forsch/Drug Res 34:1010–1017
Van der Vies J (1987) Maturitas (1987) Suppl 1:15–24
Livial, Wiss Information der Fa. Organon (1991)
Markiewicz L, Gurpide E (1990) J Steroid Biochem 35:535–541
Tang B, Markiewicz L, Kloosterboer H, Gurpide E (1993) J Steroid Biochem 45:345–351
Markiewicz L, Gurpide E (1994) J Steroid Biochem Molec Biol 48:89–94
Franchimont P, Franchi F, Luisi M, Kicovic PM (1982) Reproduccio 6:61–67
Genazzani AR, Benedek-Jaszmann LJ, Hart DM, Andolsek L, Kicovic PM, Tax L (1991) Maturitas 13:243–251
Fotherby K (1974) Acta Endocrinol Suppl 185:119–147
Milner M, Sinnott M, Gasparo D, Kelly A, Carole B-K, Harrison R (1996) J North Amer Menopause Soc 3:208–213
Benedek-Jasmann LJ (1987) Maturitas Suppl. 1:25–33
Tax L, Goorissen EM, Kicovic PM (1987) Maturitas Suppl 1:3–13
Rymer J, Champamn MG, Fogelman I, Wilson POG (1994) Maturitas 18:127–133
Ross LA, Alder EM (1995) Maturitas 21:127–136
Meuwissen JHJM, Wiegerinck MAHM, Haverkorn MJ (1995) Maturitas 21:121–125
Palacios S, Menedez C, Jurado AR, Castaño R, Vargas JC (1995) Maturitas 22:155–161
Egarter C, Huber J, Leikermoser R, Haidbauer R, Pusch H, Fischl F, Putz M (1996) Maturitas 23:55–62
Riggs BL, Tabor P, Taqbor R (1996) J Clin Endocrinol Metab 81:2417–2418
Taskin O, Yalcinoglu AL, Kucuk S, Uryan I, Buhur A, Burak F (1997) Fert Steril 67:40–45
O’Brien MER, Montes A, Powles TJ (1996) Br J Cancer 73:1086–1088
Rymer J Fogelman I, Chapman MG (1994) Br J Obstet Gynecol 101:53–56
Ginsburg J, Prelevic GM (1996) Maturitas 24:107–110
Kloosterboer HJ, Benedek-Jasmann LJ, Kicovic PM (1990) Maturitas 12:37–42
Hopkins KD, Parker JR, Lehmann ED, Rymer J, Holly JMP, Fogelman I, Cwyfan-Huges S, Teale JD, Gosling RG (1995) Horm Metab Res 27:387–388
Kloosterboer HJ, Schoonen WGEJ, Deckers GH, Klijn JGM (1994) J Steroid Biochem Molec Biol 49:311–318
Chetrite G, Kloosterboer HJ, Pasqualini JR (1997) Anticancer Res 17:135–140
Fukushima H, Suzuki Y (Nisshin Flour Milling Co., Ltd.) Brit 1501149 und 1501150; Ger Offen 2631080 zit nach Lit. 2
Thorpe PJ (1982) Drug Fut 7:889–890
Yonezawa K, Sato K, Kobayashi A (1985) J Chromatogr 339:219–222
Nakagawa Y, Sugai T, Chin WP, Shibuya T, Hashimoto K, Imai S (1984) Pharmacological profile of a new beta-adrenoceptor blocker, 4-[3-(tert-butylamino)-2-hydroxypropoxy]-N-methylisocarbostyril hydrochloride (N-696). Arzneimittelforschung 34:194–199
Imaizumi T, Takeshita A, Nakamura N, Hirooka Y, Szuzki S, Yoshida M, Nakamura M (1988) Vasodilating effect of the new beta-blocker tilisolol hydrochloride in humans. Arzneim.forsch 38:1342–1344
Sugai T, Kojima K, Iwakami N, Suzuki Y (1991) Vasorelaxant and hypotensive effects of tilisolol hydrochloride (N-696) in isolated rat thoracic aorta and pithed rats. Jpn J Pharmacol 57:367–375
Liu Q, Nakae I, Takahashi M, Takaoka A, Kinoshita M (1996) Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs. Cardiovasc Drugs Ther 10:23–30
Miyauchi H, Horiki S, Horio T (1994) Clinical and experimental photosensitivity reaction to tilisolol hydrochloride. Photodermatol Photoimmunol Photomed 10:255–258
Drugs Fut (1985) 10:182
Vitté C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324–2333
Fleisch H (1991) Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919–944
Watts NB (1994) Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 20:717–734
Fleisch H (1994) Bisphosphonates: pharmacology. Sem Arthritis Rheum 23:261–262
Reginster JY, Colson F, Morlock G (1992) Evaluation of the efficacy and safety of oral tiludronate in Paget’s disease of bone. Arthritis Rheum 35:967–974
Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P (1989) Prevention of postmenopausal bone loss by tiludronate. Lancet II: 1469–1471
Dtsch Pat. (1978) 2800536, zit. nach CA 89:129389
Kleemann A, Heese J, Engel J (1981) Arzneim Forsch 31:1178–1183
Engel J, Bork A, Nonnenmacher G, Schmidt I (1979) Chem Ztg 103:283–284
Lechner H, Ott E (1978) The influence of tinofedrine on fibrinogen and platelet aggregation in patients with recent cerebral infarction. Klin Wschr. 56:1137–1138
Merory J, Du Boulay GH, Marshall J, et al. (1978) Effect of tinofedrine (Homburg D8955) on cerebral blood flow in multiinfarct dementia. J Neurol Neurosurg Psychiatry 41:900–902
Obermeier K, Niebsch G, Thiemer K, et al. (1978) Untersuchungen zu Pharmakokinetik und Metabolismus von Tinofedrin. Arzneimittelf. 28:1360–1367
Ott E, Lechner I (1981) The effect of tinfedrine on brain perfusion in patients with cerebrovascular insufficiency. Z Gesamt Inn Med 36:124–126
Thiemer K, Obermeier K (1981) Einfluß von Tinofedrin auf den Sauerstoff-, Glukose-und Lactat-Stoffwechsel des Hundes und der Ratte. Arzneimittelf. 31:693–700
Verstraete M (1990) Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40:498–530
Kristensen HI, Ostergaard PB, Nordfang O, Abildgaard U, Lindahl AK (1992) Effect of tissue factor pathway inhibitor (TFPI) in the Heptest® assay and in an amidolytic anti factor Xa assay for LMW heparin. Thromb Haemost 68:310–314
Siegbahn A, Hassan SY, Boberg J, Bylund H, Neerstrand HS, Ostergaard P, Hedner U (1989) Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-NOVO. Thromb Res 55:767–778
Friedel HA, Balfour JA (1994) Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 48:638–660
Diness V, Nielsen JI, Pedersen PC, Wolffbrandt KH, Ostergaard PB (1986) A comparison of the antithrombotic and haemorrhagic effects of a low-molecular weight heparin (LHN-1) and conventional heparin. Thromb Haemost 55:410–414
Matthiasson SE, Lindblad B, Stjernquist U, Bergqvist D (1995) The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 25:203–211
Pedersen PC, Ostergaard PB, Hedner U, Bergqvist D (1995) Pharmacokinetics of a low molecular weight heparin, Logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 61:477–487
Dawes J, Bara L, Billaud E, Samama M (1986) Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 16:116–122
Mätzsch Th, Berqvist D, Hedner U, Ostergaard P (1987) Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healty volunteers. Thromb Haemost 57:97–101
Johansen PB, Rasmussen SN, Ostergaard PB (1994) Pharmacokinetics of tinzaparin (Logiparin®) — a low molecular weight heparin — after single and repeated intravenous administration in rats. Thromb Res 75:453–464
Leizorovicz A, Picolet H, Peyrieux JC, Boissel JP, HBPM Research Group (1991) Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 78:412–416
Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliot CG, Lerner RG, Hall J, Sparling T, Brettell HR, Ward J, Mayo W, Rosenbloom D, Brandt R (1992) Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326:975–982
Bergqvist D, Flordal PA, Friberg B, Frisell J, Hedberg M, Ljungstrom KG, Matzsch T, Torngren S (1996) Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. Vasa 25:156–160
Hauch O, Jorgensen LN, Kolle TR, Nerstrom H, Schebye O, Jorgensen PW, Ostergaard P (1988) Low molecular weight heparin (Logiparin®) as thromboprophylaxis in elective abdominal surgery. Acta Chir Scand Suppl 543:90–95
Christiansen HM, Lassen MR, Borris LC, Sorensen JV, Rahr HB, Jorgensen LN, Jorgensen PW, Hauch O (1991) Biologic tolerance of two different low molecular weight heparins. Semin Thromb Haemost 17:450–454
Samama M (1989) Correlation between anti Xa activity and occurence of DVT and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or standard heparin. Thromb Haemost 62:1470
Holst J, Lindblad B, Bergqvist D, Garre K, Nielsen H, Hedner U, Ostergaard PB (1994) Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin ™). An experimental investigation in healthy volunteers. Blood Coagul Fibrinol 5:795–803
Tinzaparin (innohep®) Product Monograph, Leo Pharmaceutical Products, Ballerup, Dänemark, 1992
ABDA, Pharmazeutische Stoffliste
Wunderlich H, Stark A, Carstens E, Lohmann D, Gritsenko AN, Skoldinov AP (1985) Pharmazie 40(12):827–830
Mayer W, Usbeck H, Rodionov AP (1985) Pharmazie 40(12):832–835
Nemeth M, Varro A, Papp JG (1995) Electrophysiological effects of tiracizin and is metabolites in dog cardiac Purkinje fibers. Gen Pharmacol 26:793–798
Volkmann H, Kuhnert H, Dannberg G, Heinke M, Leeder U, Popp U (1991) Elektrophysiologische und antiarrhythmische Effekte von Tiracizin bei ventrikulären Tachykardien. Z Gesamte Inn Med 46:635–641
Berndt A, Gramatte T, Oertel R, Richter K, Terhaag B, Kirch W (1994) Dose dependent tiracizine disposition in healthy volunteers: serum and urine kinetics and dose related ECG-changes. Eur J Drug Metab Pharmacokinet 19:359–368
Berndt A, Oertel R, Terhaag B, Richter K, Gramatte T (1995) Pharmacokinetics of the antiarrhythmic agent tiracizine: steady state kinetics in comparison with single-dose kinetics. Biopharm Drug Dispos 16:427–441
The STIPAS Investigators (1994) Safety study of tirilazad mesylate in patients with acute ischaemic stroke (STRI-PAS). Stroke 25:418–423
Haley EC (1995) Phase II trial of tirilazad in aneurysmal subarachnoid haemorrhage: A report of the Cooperative Aneurism Study. J Neurosurg 82:786–790
Braughler JM, Hall ED, Jacobsen EJ, McCall JM, Means ED (1989) Drugs Fut 14:143–152
Jacobsen EJ, McCall JM, Ayer DE, VanDoornik FJ, Palmer JR, Belonga KL, Braughler JM, Hall ED, Houser DJ, Krook MA, Runge TA (1990) J Med Chem 33:1145–1151
Parker KA, Coburn CA (1992) J Org Chem 57:97–100
Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470–474
Spence RA, Kati WM, Anderson KS, Johnson KA (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988–993
de Vreese K, Debyser Z, Vandamme AM, Pauwels R, Desmyter J, de Clercq E, Anne J (1992) Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Virology 188:900–904
Pauwels R, Andries K, Debyser Z, Kukla MJ, Schols D, Breslin HJ, Woestenborghs R, Desmyter J, Janssen MA, de Clercq E, Janssen PA (1994) New tetrahydroimidazo [4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and-thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob Agents Chemother 38:2863–2870
De Wit S, Hermans P, Sommereijns B, O’Doherty E, Westenborghs R, van de Velde V, Cauwenbergh GF, Clumeck N (1992) Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion. Antimicrob Agents Chemother 36:2661–2663
Pialoux G, Youle M, Dupont B, Gazzard B, Cauwenbergh GF, Stoffels PA, Davies S, de Saint Martin J, Janssen PA (1991) Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex. Lancet 338:140–143
DE 1936695, zit. nach CA (1971) 74:53774
Clemence F, LeMartret O, Fournex R, Dagnaux M et al. (1976) Eur J Med Chem 11:567–570
Hansch C, Sammes PG, Taylor JB (Hrsg.) (1990) Comprehensive Medicinal Chemistry, Pergamon Press, Oxford, Bd. 6, S. 915
DE 2422849, zit. nach CA (1975) 82:72977
Kirkpatrick D, Girkin R, Chasseaud LF, Hawkins DR et al. (1980) Xenobiotica 10:797–803
Pharmeuropa (1995) 7:163-165
Cheeseman KH, Holley AE, Kelley FJ, Wasil M, Hughes L, Burton G (1995) Free Rad Biol Med 19:591
Buettner GR (1993) Arch Biochem Biophys 300:535
Maiorino M, Coassin M, Roveri A, Ursini F (1989) Lipids 24:721
Traber M, Kayden HJ (1989) Am J Clin Nutr 49:517
Sato Y, Arai H, Miyata A, Tokita S, Yamamoto K, Tanabe T, Ione K (1993) J Biol Chem 268:17705
Ouahchi K, Arita M, Kayden H, Hentati F, Ben Hamida M., Sokol R, Arai H, Inone K, Mandel J-L, Koenig M (1995) Nature Genetics 9:141
Schultz M, Leist M, Petrizika M, Gassmann B, Brigelius-Flohé R (1995) Am J Soc Clin Nutr Suppl 62:1527
Diplock AT (1993) VitaMinSpur 8:11
Steinert M (1991) J Am Coll Nutr 10:466
Tran K, Chan AC (1990) Biochim Biophys Acta 1043:189
Pharmeuropa (1995) 7:168
Charpentier A, Groves S, Simmons-Menchaca M, Turley J, Zhao B, Sanders BG, Kline K (1993) Nutr Cancer 19:225
Turley JM, Sanders BG, Kline K (1992) Nutr Cancer 18:201
Israel K, Sanders BG, Kline (1995) Nutr Cancer 24:161
Fariss MW, Fortuna MB, Everett CK, Smith JD, Trent DF, Djuric Z (1994) Cancer Res 54:3346
Cohrs RJ, Torelli S, Prasad KN, Edwards-Prasad J, Sharma OK (1991) Int J Dev Neurosci 9:187
Prasad KN, Edwards-Prasad J (1992) J Am Coll Nutr 11:487
Prasad KN, Edwards-Prasad J, Kumar S, Meyers A (1993) Arch Otolaryngol Head Neck Surg 119:1133
Romach EH, Kidao S, Sanders BG, Kline K (1993) Nutr Cancer 20:205
Kidao S, Sanders BG, Kline (1993) Biotechnol Ther 4:117
Kline K, Sanders BG (1993) Nutr Cancer 19:241
Cheeseman KH, Holley AE, Kelly FJ, Wasil M, Hughes L, Burton G (1995) Free Rad Biol Med 19:591
Pearce BC, Parker RA, Deason ME, Qureshi AA, Wright JJK (1992) J Med Chem 35:3595–3606
Cimino G, De Rosa S, De Stefano S, Morrone R, Sodano G (1985) Tetrahedron 41:1093–1100
Urano S, Nakano SI, Matsuo M (1983) Chem Pharm Bull 31:4341–4345
Choo YM, Ma AN, Yahaya H, Yamanouchi Y, Bounositha M, Sails M (1996) J Am Oil Chem Soc 73:523–525; zit. nach CA 124:287549
Perricone N (1994) US 5376361; zit. nach CA 122:89135
Komiyama K, Iizuka K, Yamaoka M, Watanabe H, Tsuchiya N, Umezawa I (1989) Chem Pharm Bull 37:1369–1371
Suzuki YJ, Tsuchiya M, Wassall SR, Choo YM, Govil G, Kagan VE, Packer L (1993) Biochemistry 32:10692–10699
Serbinova EA, Packer L (1994) Meth Enzymol 234:354
Suarna C, Hood RL, Dean RT, Stocker R (1993) Biochim Biophys Acta 1166:163
Kamal-Eldin A, Appelquist LA (1996) Lipids 31:671
Qureshi AA, Qureshi N, Wright JJ, Shen Z, Kramer G, Gapor A, Chong YH, DeWitt G, Ong A, Peterson DM (1991) Am J Clin Nutr Suppl 53:1021
Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ (1993) J Biol Chem 268:11230
Qureshi N, Qureshi AA (1993) Packer L, Fuchs J (eds) in: Vitamin E in Health and Disease Marcel Dekker, Inc, New York, Basel, Hongkong, p 247
Qureshi AA, Bradlow BA, Brace L, Manganello J, Peterson DM, Pearce BC, Wright JJ, Gapor A, Elson CE (1995) Lipids 30:1171
Nesaretnam K, Guthrie N, Chambers AF, Carroll KK (1995) Lipids 30:1171
Hayes KC, Pronczuk A, Liang JS (1993) Proc Soc Exp Biol Med 202:353
Drugs Fut (1991) 16(8):719-721
Borgulya J, Bruderer H, Bernauer K, Zürcher G, Da Prada M (1989) Helv Chim Acta 72:952–968
Oberdisse E, Hackenthal E, Kuschinski K (Hrsg.) (1997) Pharmakologie und Toxikologie, Springer-Verlag, Berlin Heidelberg
Nürnberg B (1994) Pharmazie 49, 795–800
Baas H, Deuschl G, Oertel W, Poewe W (1997) Deutsch Apoth Ztg 137, 860–866
Hagan JJ, Middlemiss DN, Sharpe PC, Poste GH (1997) Trends Pharmacol Sci 18, 156–163
Peruche B, Schulz M (1997) Pharmazeut Ztg 143, 932–937
Tasmar® 100 und 200, Fachinformationen. Roche Registration Ltd., Welwyn Garten City, UK vom 24.10.1997
NL (1966) 6,600,251 (Gea A/S), zit. nach CA (1967) 66:2377
Scherrer RA, Short FW (Parke Dayvis) (1967) US 3,313,848, zit. nach CA (1967) 67:73368
Nielsen-Kudsk F (1980) Acta Pharmacol Toxicol 47(4):267–273
Papadoyannis I, Georgarakis M, Samanidou V, Zotou A (1991) J Liq Chromatogr 14(15):2951–2967, zit. nach CA(1991) 115:239894
Papadoyannis I, Zotou A, Samanidou V (1992) J Liq Chromatogr 15(11): 1923–1945, zit. nach CA (1992) 117:76615
Niopas I, Georgarakis M (1995) J Liq Chromatogr 18(13):2675–2682, zit. nach CA (1995) 123:187592
Gonzalez G, Ventura R, Smith AK, de la Torre R, Segura J (1996) J Chromatogr A 719(1):251–264
Cardenas S, Gallego M, Valcarcel M, Ventura R, Segura J (1996) Anal Chem 68(1):118–123
Kim KR, Shim WH, Shin YJ, Park J et al. (1993) J Chromatogr 641(2):319–327
Shinozuka T, Terada M, Ogamo A, Nakajima R et al. (1996) Jpn J Forensic Toxicol 14(3):246–252, zit. nach CA (1997) 126:43681
Kaukinen A (1979) Acta Pharm Fenn 88:53–61
Clarke CGE (1969) Isolation and Identification of Drugs, The Pharmaceutical Press, London
Feigl F (1966) Spot Tests in Organic Analysis, 7. Aufl., Elsevier Publishing Company, Amsterdam, S.457
Vane JR, Botting RM (1995) A better understanding of anti-inflammatory drugs based on isoforms of COX. Adv Prost Thromb Leuko Res 23:41–48
Vane JR, Botting R (1996) Overview — mechanisms of action of anti-inflammatory drugs. In: Vane JR, Botting J, Botting R (eds) Improved anti-inflammatory drugs COX-2 enzyme inhibitors. Lancester: Kluwer Academic Publisher
Kankaanranta H, Luomala M, Kosonen O, Moilanen E (1996) Inhibition by fenamates of calcium influx and proliferation of human lymphocytes. Br J Pharmacol 119(3):487–494
Kankaanranta H, Moilanen E, Vapaatalo H (1993) Comparison of in vitro effects of flunixin and tolfenamic acid on human leukocyte and platelet functions. Inflammation 17(4):417–425
Kankaanranta H, Moilanen E (1995) Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes. Mol Pharmacol 47(5):1006–1013
Tolfenamic acid. Summary Report (1997) The European Agency for the Evaluation of medical products. 7 Westferry Circus, Canary Warf, London
Mikkelsen B, Pedersen KK, Christiansen LV (1986) Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand (7384):423–427
Hakkarainen H, Vapaatalo H, Gothoni G, Prantainen J (1979) Tolfenamic acid is as effecitve as ergotamine during migraine attacks. Lancet 2(8138):326–328
Mikkelsen BM, Falk JV (1982) Prophylactic treatment of migraine with tolfenamic acid. A comparative double-blind crossover study between tolfenamic acid and placebo. Acta Neurol Scand 66(1):105–111
Larsen BH, Christiansen LV, Andersen B, Olesen J (1990) Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol Scand 81(5):464–4675
Hansen PE (1994) Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol Toxicol 75 Suppl 2:81–82
Pentikainen PJ, Neuvonen PJ, Backman C (1981) Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol 19(5):359–365
Pedersen SB (1994) Biopharmaceutical aspects of tolfenamic acid. Pharmacol Toxicol 75 Suppl 2:22–32
Tokola RA, Anttila VJ, Neuvonen PJ (1982) The Effect of metoclopramide on the absorption of tolfenamic acid. Int J Clin Pharmacol Ther Toxicol 20(10):465–468
Niopas I, Georgarakis M, Sidi-Frangandrea V, Chrisanthopoulos C, et al. (1995) Pharmacokinetics of tolfenamic acid in pediatric patients after single oral dose. Eur J Drug Metab Pharmacokinet 20(4):293–296
Pedersen SB, Alhede B, Buchardt O, Moller J, et al. (1981) Tolfenamic acid. Detection and structure of urinary metabolites. Arzneimittelforschung 31(11):1944–1948
Pentikainen PJ, Penttila A, Neuvonen PJ, Khalifah RG, et al. (1982) Human metabolism of tolfenamic acid. I Isolation, preliminary characterization and pharmacokinetics of tolfenamic acid and its metabolites. Eur J Drug Metab Pharmacokinet (4):259–267
Pentikainen PJ, Tokola O, Alhava E, Penttila A (1984) Pharmacokinetics of tolfenamic acid: disposition in bile, blood and urine after intravenous administration to man. Eur J Clin Pharmacol 27(3):349–354
Isomaki H (1994) Tolfenamic acid: clinical experience in rheumatic deseases. Pharmacol Toxicol 75 Suppl 2:64–65
Tolfenamic acid (1985) Martindale — The Extra Pharmakopoeiy. The Pharmaceutical Press, London S36:1520, 1806
Myllyla VV, Havanka H, Herrala L, Kangasniemi P, et al. (1998) Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 38(3):201–207
Delgado J, Simonin G, Servier C, Gacria R, et al. (1994) Tolfenamic acid and mefenamic acid in the treatment of primary dysmenorrhoea. Pharmacol Toxicol 75 Suppl 2:89–91
Rejholec V, Vapaatalo H, Takola O, Gothoni G (1980) Tolfenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin. Scand J Rheumatol Suppl 36:1–7
Nakatsumi Y, Nomura M, Yasui M, Fujimura M, et al. (1993) A case of eosinophilic pneumonia due to tolfenamic acid. Nippon Kyobu Shikan Gakkai Zasshi 31(10):1322–1326
Strömberg C, Palva E, Alhava E, Aranko K, et al. (1987) Pulmonary infiltrations induced by tolfenamic acid. Lancet 2(8560):685
Johnson AG, Seideman P, Day RO (1993) Adverse drag interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). recognition, management and avoidance. Drag Saf 8(2):99–127
Laznicek M, Senius KE (1986) Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease. Eur J Clin Pharamcol 30(5):591–596
Neuvonen PJ, Kivisto KT (1994) Enhancement of drag absorption by antacids. An unrecognised drag interaction. Clin Pharmacokinet 27(2):120–128
Vale JA, Meredith TJ (1986) Acute poisoning due to non-steroidal anti-inflammatory drags. Clinical features and management. Med Toxicol 19861(1):12–31
Drugs Fut (1984) 9(9):670-672
Sestanj K, Bellini F, Fung S, Abraham N, Treasurywala A, Humber L, Simard-Duquesne N, Dvornik D (1984) J Med Chem 27(3):255–256
Giugliano D, Marfella R, Quatraro A, De-Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R (1993) Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Ann Intern Med 118:7–11
Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang KY, Gabbay KH, Rubenstein AH, Porte D (1983) Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. New Engl J Med 308:119–125
Eur Pat Appl 46pp. EP 321122 A2 890621
Herbon VMM, ten Bokkel Huinink W, Beijnen JH (1996) Clin Pharmacokinet 31:85–102
Champoux J (1976) Proc Natl Acad Sci USA 73:3488–3491
Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M (1989) Cancer Res 49:4385–4389
Zhang H, D’Arpa P, Liu LF (1990) Cancer Cells 2:23–27
Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD (1994) Cancer Chemother Pharmacol 34:171–174
McCabe Fl Johnson RK (1994) Cancer Invest 12:308–313
Chang AY, Garrow G, Boros L, Asbury K, Pandya K, Keng P (1995) Proc Am Soc Clin Oncol 14:105
Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC (1992) J Clin Oncol 10:647–656
Grochow LB, Slichenmyer W, Rowinsky E, Donehower R, Foastiere A, Chen TL (1994) Ann Oncol 5:191 (Suppl 5, abstract 462)
Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hard M, Verschraegen C, Raber M, Kavanagh JJ (1996) J Clin Oncol 14:1552–1557
Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, van Belle S, Hudson I, Verweij J (1996) J Clin Oncol 14:3056–3061
Gordon A, Bookman M, Malmstrom H, Bolis G, Mangioni C, Hall J, Carter J, Hudson I, Broom C (1996) Proc Am Soc Clin Oncol 15:282
Carmichael J, Gordon A, Malfetano J, Gore M, Spaczynski M, Davidson N, Savage J, Clarke-Pearson D, Hudson I, Broom C, ten Bokkel Huinink W (1996) Proc Am Soc Clin Oncol 15:283
Schiller JH, Kim KM, Hutson P, Devore R, Glick J, Stewart J, Johnson D (1996) J Clin Oncol 14:2345–2352
Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J (1997) J Clin Oncol 15:2090–2096
Takimoto CH, Arbuck SG (1996) The Camtothecins. In: Chabner BA and Longo DL (ed) Cancer Chemotherapy and Biotherapy. Lippincott-Raven Publishers, Philadelphia, S. 463
Mross K, Unger C (1997) Arzneimitteltherapie 15:171–179
Urbuch H, Henning R, Teetz V, Geiger R, Becker R, Gaul H ( Hoechst A.G.) Drugs Fut (1989) 14:778–780
Brion F, Marie C, Mackiewicz P, Roul JM, Buendia J (1992) Tetrahedron Lett 33:4889–4892
Hasegawa Y, Manabe T, Hirayama M, Nishioka R (1993) Iyakuhin Kenkyu (1993) 24:273–280; zit. nach CA 119:151518
Wiseman LR, McTavish D (1994) Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 48:71–90
Con H, Brunner HR (1993) Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. American Heart Journal 125:1525–1531
Johnston CI (1990) Biochemistry and Pharmacology of the renin-angiotensin system. Drugs 39:21–31
Sanbe A, Tanonaka A, Kobayashi R, Takeo S (1995) Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril on myocardial energy metabolism in rats with heart failure myocardial infarction. J Mol Cell Cardiol 27:2209–2222
Okumura Y, Nasa Y, Sanbe A, Toga W, Takeo S (1996) Effects of long-term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure. J Cardiac Failure 2.301–310
Münter K, Hergenroder S, Jochims K, Kirchengast M (1996) Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat. J Am Soc Nephrol 7:681–686
de Leeuw PW (1995) Trandolapril: a clinical profile. Am J Hypertension 8:68S–70S
Vaur L, Dutrey-Dupagne C, Boussac J, Genes N, et al. (1995) Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 26:127–131
The Veratran Study Group (1997) Effects fo Verapamil SR, trandolapril, and their fixed combination on 24 h blood pressure: the Veratran Study. American J Hypertension 10:492–499
Arner P, Wade A, Engfeldt P, Mouren M, et al. (1994) Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 23 (Suppl 4):S44–S49
Danielson B, Querin S, LaRochelle P, Sultan E, et al. (1994) Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol 23 (Suppl 4):S50–S59
Meyer BH, Muller FO, Badenhorst NB, Luus HG, de la Rey N (1995) Multiple doses of trandolapril do not affect warfarin pharmacodynamics. South African Medical Journal 85:768–770
Blunt JE, DeLuca HF (1969) Biochemistry 8:671–675
Eric D, Lawson M, Bell PA (1974) Biochemical Journal 142:37–46
Isler O, Brubacher (1982) Vitamine I, Thieme Verlag, Stuttgart, S. 90–126
Holick MF, Garabedian M, DeLuca HF (1972) Science 176:1247–1248
von Herrath D, Schaefer K, Kraft D, Grigoleit HG, Koeppe P (1973) Klin Wschr 51:979–981
Kraft D, Schaeger K, Grigoleit H-G, Offermann G, von Herrath D, Delling G (1979) Dtsch med Wschr 104:1706–1710
Offermann G, Schaefer K, Grigoleit HG, Dittmat F (1975) Europ J Clin Pharm 8:255
Lawson EM, Bell PA (1974) Biochem J 142:37–46
Fachinformation Delakmin®, Albert Roussel Pharma GmbH (1994)
Kliem M (1980) Med Monatsschr Pharm 3:47–52
Meyer, zum Büschenfelde KH (1984) Therapiewoche 34:4005–4007
US Pat 3.020.303
Neurath AR, Strick N, Sproul P, Baker L, Rubinstein P, Stevens CE, Taylor P, Gallo RC, Gold JW, Lee YS (1985) Radioimmunoassay and enzyme-linked immunoassay of antibodies to the core protein (P24) of human T-lymphotropic virus (HTLV III). J Virol Methods 11:75–86
Trobisch H (1991) Results of a quality-control study of lyophilized pooled plasmas which have been ‘virally inactivated’ using a solvent detergent method (modified Horowitz procedure). Beitr. Infusionsther 28:92–109
Gurtler L (1994) Möglichkeiten der Virusaktivierung von gepooltem Frischplasma mit Tri-n-butylphosphat-(TNBP)-Detergenz (SD-Verfahren). Infusionsther Transfusionsmed 21 Suppl 1:77–79
Josic D, Schwinn H, Stadler M, Strancar A (1994) J Chromatogr B Purification of factor VIII and von Willebrand factor from human plasma by anion-exchange chromatography. Biomed Appl 662:181–190
Produktinformation der Fa. Apogepha
Fr. Pat. M 940, (1961) zit. nach CA (1963) 58:3354h
Rudavskii VP, Khaskin IB (1967) Ukr Khim Zh 33:391–394, zit. nach CA
Mar 31, S.958
Loefgren (1946) Ark Keni 22(18): 12; zit. aus Beilstein
CA (1964) 65:20055
Samdahl (1965) Ann Pharm Fr 23:355, 360
Ehrenberg (1948) Acta Chem Scand 2(63):71
Vakhrin M (1980) Pharm Chem J 14(4):239–244
Polasek M, Gas B, Hirokawa T (1992) J Chromatogr 596:265–270
Chmela Z, Cizmarik J, Stransky Z (1985) Pharmazie 40:731–732
Beil, Erg. Werk 3/4, Bd. 21, S. 700
Clarke ECG (1969) Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 584
Tencheva J, Velinov G, Budevsky O (1979) Arzneim Forsch 29:1331–1334
Khomov YA, Koksharova NV (1975) Farmatsiya (Moscow) 24(1):76–77, zit. nach CA (1975) 82:160310x
Zavrazhnaya TA, Kuleshova MI, Levite E, Zhukova OI (1984) Farmatsiya (Moscow), zit. nach CA (1985) 102:55533f
Goldin VA, Egbe ZE (1991) Direct infusion of drug mixture into the aorta in the treatment of necrotizing pancreatitis. Khirurigiia Mosk Jun (6):116–121
Beil Bd. 36, Teil IV, S. 1273
Mar 27, S. 1826
Tetrahedron Lett (1995) 36(12):2129-2132
J Chromatogr (1990) 499:617-625
Drugs Fut (1985) 10(7):575
(1977) Laboratory of Phytochemistry, Institute of Botany, Yunan and Pharmacologie Laboratory, Institute of Medical Science, Honan. Diterpenoid triepoxides antitumor principles from Tripterygium hypoglaucum and T. wilfor-dii, Koxne Tongbao 22(10):a158-460; zit. nach Lit.1
Kupchan SM, Court WA, Dailey RG, Gilmore CJ et al. (1972) Triptolide ans triptolidine, novel antileukemia diterpenoid triepoxides from Tripterygium wilfordii J Am Chem Soc 94(20):7194–7194; zit. nach1
Zhen QS, Ye X, Wei ZJ (1995) Recent progress in research on Tripterygium: a male antifertility plant. Contraception 51:121–129
Yang SX, Xie SS, Gao HL, Ma DL, et al. (1994) Triptolide suppresses T-lymphocyte proliferation by inhibiting inter-leukin-2 receptor expression, but spares interleukin-2 production and mRNA expression. Int J Immunopharmacol 16:895–904
Gu WZ, Chen R, Brandwein S, McAlpine J, et al. (1995) Isolation, purification, and characterization of immuno-suppressive compounds from tripterygium: triptolilde and tripdiolide. Int J Immunopharmacol 17:351–356
Pifferi G, Monguzzi R, Banfi S, Carpi C (1973) Chim Ther 8:462–465
Crolla T, Borsa M, Pifferi G (1981) J Chromatogr 222:257
Pacifici GM, Bianchetti G, Frigerio A, Morselli PL et al. (1976) Eur J Drug Metab Pharmacokinet 1:141
Bianchi-Porro G, Petrillo M, Ferrara A, Abbondati G (1976) Minerva Gastroenterol 22:149–152
Barbara L, Corinaldesi R, Miglioli M, Guidoboni R, Luchetta L, Lami F, Labo G (1975) Minerva Gastroenterol 21:169–183
Drugs Fut (1984) 14(9):846-848
Lee MK, Olefsky JM (1995) Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 44:1116–1169
Ciaraldi TP, Huber-Knudsen K, Hickmann M, Olefsky JM (1995) Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism 44:976–981
Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H (1994) Effects of an new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11:685–691
Masuda K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y (1995) Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24–30
Fujiwara T, Okuno A, Yoshioka S, Horikoshi H (1995) Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 44:486–490
Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K (1995) Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hy-pertens 8:316–320
Witt (1879) Chem Ber 12:258
Forster et al. (1957) J Chem Soc 3575-3577
Mar 31, S.508
Fozard JR, Gittos MW (1986) US Ser. No. 386:562; zit. nach CA 105:54608
Azria M, Buchheit KH, Dixon KA, Engel G, Giger RKA (1988) Ger Offen DE 3,724,059; zit. nach CA (1989) 110:8041z
Veyrath-Follet C, Farinotti R, Palmer JL (1997) Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Drugs 53:206–234
Gyermek L (1995) 5-HT3-receptors. Pharmacologic and therapeutic aspects. J Clin Pharmacol 35:845–855
Tyers MB, Freeman AJ (1992) Mechanism of the anti-emetic activity of 5-HT3-receptor antagonists. Oncology 49:263–268
Sorbe B, Berglind AM (1992) Tropisetron, a new 5-HT3-receptor antagonist, in the prevention of radiation-induced nausea, vomiting and diarrhoea. Drugs 43 Suppl 3:33–39
Aapro MS (1991) 5-HT3-receptor antagonists. An overview of their present status and future potential in cancer chemotherapy-induced emesis. Drugs 42:551–568
Lee CR, Plosker GL, McTavish D (1993) Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antemetic. Drugs 46:925–943
Dumuis A, Bouhelal R, Sebben M, Bockaert J (1988) 5HT receptor in the central nervous system positively coupled with adenyl cyclase, is antagonized by JCS 205–930. Eur J Pharmacol 146:187–188
Fricke U, Klaus W (1995) Neue Arzneimittel 1994. S 107-120. Wiss Verlagsges. Stuttgart
de Bruijn KM (1992) Tropisetron: A review of the clinical experience. Drugs 43 Suppl 3:11–22
Bruntsch U, Drechsler S, Hiller E, Eiermann W, Tulusan AH, Bühner M, Hartenstein R, König HJ, Gallmeier WM (1992) Prevention of chemotherapy-induced nausea and emesis in patients responding poorly to previous antiemetic therapy: comparing tropisetron with optimised standard antiemetic therapy Drugs 43 Suppl 3:23–26
Dogliotti L, Antonacci RA, Paze E, Ortega C, Berutti A, Faggiuolo R (1992) Three years experience with tropise-tron in the control of nausea and vomiting in cisplatin-trea-ted patients. Drugs Suppl 3:6–10
De Witt R, Boer-Dennert M, Stoter G, Verweij J (1992) Sustainment of efficacy of tropisetron during 6 courses of cisplatin containing chemotherapy. Ann Oncol 3 Suppl 5:185
Zomers PJW, Langenberg CJM, de Bruijn KM (1993) Tropisetron for postoperative nausea and vomiting in patients after gynecological surgery. Brit J Anaesth 71:677–680
Castaner J (1991) Drugs Fut 16:323–330
White DR, Cain GA (1989) Tetrahedron Lett 30:1469–1472
Herrington PM, Klotz KL, Hartley WM (1993) J Org Chem 58:678–682
LikarMD, Taylor RJ, FagernessPE, HiyamaY, Robins RH (1993) Pharm Res 10:75–79
Simmonds RJ, Wood SA, Ackland MJ (1990) J Liq Chro-matogr 13:1125–1142
Mar 31, S.294
Nichols DJ, Bye A, Novak E (1991) Pharmacokinetics of trospectomycin sulphate in healthy subjects after single intravenous and intermuscular doses. Br J Clin Pharmacol 32:255–257
Fromtling RA, Castaner J (1996) Drugs Fut 21(5):496–505
Haria M, Lamb HM (1997) Drags 54:435–445
Fachinformation Trovan, Fa. Pfizer
Christ W, Kemmler H, Esch B ((im Druck)) Verträglichkeit und Anwendungssicherheit von Fluorchinolonen, Spezifische toxikologische Aspekte und Nebenwirkungen, FAC Fortschritte der antimikrobiellen und antineo-plastischen Chemotherapie, 16-21
Fachinformation Trovan (Deutschland) US-amerikanische Produktinformation, Fa. Pfizer
European Public Assessment Report des CPMP, erhältlich bei der European Agency for the Evaluation of Medicinal Products, London
DiSalle E, Giudici D, Briatico G, Omati G, Panzeri A (1993) J Steroid Biochem Molec Biol 46:549–555
DiSalle E, Briatico G, Giudici D, Ornati G, Panzeri A (1994) J Steroid Biochem Molec Biol 48:241–248
Lehlè C, Dèlos S, Guirou O, Täte R, Raynaud J-P; Martin P-M (1995) J Steroid Biochem Molec Biol 54:273–279
Zaccheo T, Guidici D, DiSalle E (1997) Prostate 30:85–91
Persiani S, Broutin F, Pianezzola E, Panzeri A, Fonte G, Fontana E, Strolin Bendedetti M (1994) J Immunoassay 15:97–113
Bisileo G, Casati M, Pianezzola E, Strolin Benedetti M (1997) J Chromatogr B 688:117–125
Drugs Fut (1993) 18(5):436-439
Mar 28
Paesen J, Claeys P, Cypers W, Roets E, Hoogmartins J (1995) J Chromatogr 699:99–106
Fish BJ, Carr GPR (1986) J Chromatogr 353:39–50
Paesen J, Claeys P, Cypers W, Roets E, Hoogmartins J (1995) J Chromatogr 699:93–97
Bobillot S, Bakos T, Sarda P, Thang TT, Ming L, Olesker A, Lukacs G (1995) chemical modification of tylosin. J Antibiotics 48:667–670
Nguyen LT, Nguyen KT, Spizek J, Behal V (1995) The ty losin producer, Streptomyces fradiae, contains a second valine dehydrogenase. Microbiology 141:1139–1145
Wilson RC (1984) The macrolides. In: Steele JH, Beran GW (Hrsg.) CRC Handbook Series in Zoonoses. Section D. Band 1, CRC Press, Inc, Boca Raton, Florida, S. 305–331
Atef M, Yousseff SAH, Atta AH, El-Maaz AA (1991) Disposition of tylosin in goats. Br vet J 147:207–215
Ziv G, Creveld CV, Ben-Zvi Z, Glickman A, Yagil R (1995) Disposition kinetics of tylosin tartrate administered intravenously and intramuscularly to normal and water-deprived camels. J Vet Pharmacol Therap 18:299–305
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
von Bruchhausen, F. et al. (1999). T. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-58388-9_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63569-4
Online ISBN: 978-3-642-58388-9
eBook Packages: Springer Book Archive